CC-92328 / BMS, Dragonfly Therap - LARVOL DELTA

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=26 | Terminated | Sponsor: Celgene | N=70 ➔ 26 | Trial completion date: Jun 2026 ➔ Jun 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jul 2025 ➔ Jun 2024; Business objectives have changed

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=70 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Celgene | Trial primary completion date: Nov 2025 ➔ Jul 2025

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: Celgene | Trial completion date: Feb 2026 ➔ Jun 2026 | Trial primary completion date: Feb 2026 ➔ Nov 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Celgene; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET Immunotherapies (PRNewswire) - "Dragonfly Therapeutics, Inc...announced that Bristol Myers Squibb has licensed a fifth TriNKET™ Immunotherapy drug candidate, bringing the total drug candidates licensed by Bristol Myers Squibb to six including Dragonfly's novel IL-12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies have agreed to two additional collaborations which include oncology and neuroinflammation targets....Dragonfly also announced that the first patients have been dosed in Phase 1 clinical trials of both the CC-96191 and CC-92328 investigational immunotherapies, which are licensed to Bristol Myers Squibb."

Licensing / partnership • Trial status • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: Celgene

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology